Aktuellt
SENASTE
Redeye maintains its optimistic view on 2cureX following today’s report. With an ongoing European commercialization of IndiTreat as well as an imminent launch of a new test for patients with mCRC in 1st line, we argue that the company has interesting times ahead. The stock is currently trading far below our Base Case.
LÄS MER
